Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Sci's Innova OK'd By FDA To Treat Peripheral Artery Disease

This article was originally published in The Gray Sheet

Executive Summary

The vascular self-expanding stent system has been approved as an advanced treatment for patients with narrowing or blockages in their superficial femoral artery or proximal popliteal artery, which can lead to peripheral artery disease – a condition that affects 8 million Americans.

You may also be interested in...



Corrosion Testing For Nickel Stents Front And Center In FDA Final Update

The agency says it has taken into account feedback from industry during a 2013 workshop on the risks of nickel stents, and has reduced its requirements for standard corrosion testing while also outlining steps on when to adopt different corrosion testing methods.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel